Showing 7741-7750 of 8649 results for "".
- US Eye Network Expands into Southeastern US through Partnership with Carolina Eyecare Physicianshttps://modernod.com/news/us-eye-network-expands-into-southeastern-us-through-partnership-with-carolina-eyecare-physicians/2478319/Carolina Eyecare Physicians has joined the expanding US Eye network. With the addition of Carolina Eyecare Physicians, US Eye, a physician-led network of practices, will operate 24 clinics and 3 surgery centers. <
- CooperVision Recaps Complimentary Contact Lens Program for Essential Hospital Workershttps://modernod.com/news/coopervision-recaps-complimentary-contact-lens-program-for-essential-hospital-workers/2478307/Over the past 4 months, CooperVision’s Essential Hospital Workers Complimentary Contact Lens Program enabled eye care professionals to provide support to patients working on the front lines of the COVID-19 pandemic. By the program’s conclusion on August 31, nearly 570 optometry practices from 46
- Moody’s: Hospital Financial Outlook Worse as COVID-19 Relief Funds Start to Dwindlehttps://modernod.com/news/moodys-hospital-financial-outlook-worse-as-covid-19-relief-funds-start-to-dwindle/2478308/For-profit hospitals are expected to see a financial decline over the next 12 to 18 months as federal relief funds that shored up revenue losses due to COVID-19 start to wane, a recent analysis from Moody’s said, according to a FierceHealthcare
- Liminal BioSciences Provides Update on Progress on BLA for Ryplazim (Plasminogen)https://modernod.com/news/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen/2478301/Liminal BioSciences announced that the FDA acknowledged receipt of the resubmission of the Biologic License Application (BLA) for Ryplazim (plasminogen) for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency (C-PLGD) in pediatrics and adults. The
- BioNTech Snaps Up Novartis’ German Site to Expand Coronavirus Vaccine Outputhttps://modernod.com/news/biontech-snaps-up-novartis-german-site-to-expand-coronavirus-vaccine-output/2478296/BioNTech announced that it signed a share purchase agreement to acquire Novartis’ manufacturing facility in Marburg, Germany, a move it says will bolster its COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month. BioNTech, whose Pfizer-
- Ophthalmic Societies Call on FDA to Keep Moxifloxacin on Bulk Substance Listhttps://modernod.com/news/ophthalmic-societies-call-on-fda-to-keep-moxifloxacin-on-bulk-substance-list/2478293/Several ophthalmic organizations have collectively sent a letter to the FDA requesting that the agency retain moxifloxacin as Category 1 for outsourcing facility use (503b), citing a demonstrated clinical need for the medication as a bulk substance. The request comes after the FDA, on July 31, ga
- Medscape US and International Physicians’ COVID-19 Experience Report: Risk, Burnout, Lonelinesshttps://modernod.com/news/medscape-us-and-international-physicians-covid-19-experience-report-risk-burnout-loneliness/2478285/Physicians worldwide have put their physical and mental health at risk as they battled the coronavirus pandemic. In Medscape’s COVID-19 survey, almost 7,500 physicians from the United States, Brazil, France
- Keeler Partners With Medical Device Maker Olleyeshttps://modernod.com/news/keeler-partners-with-medical-device-maker-olleyes/2478278/Keeler has announced a partnership with Olleyes, a developer of eye care-based office and home-based diagnostic products. Terms of the deal were not disclosed. Olleyes is the maker of VisuALL VRP (Virtual Reality Perimetry), a platform designed for standardized and mobile assessment
- First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Post-Surgical Ocular Inflammation and Pain in Childrenhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-post-surgical-ocular-inflammation-and-pain-in-children/2478274/Ocular Therapeutix announced that it has dosed the first patients in a phase 3 clinical trial of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce the start o
- 5 Reasons Why Medical Meetings Will Never Be the Samehttps://modernod.com/news/5-reasons-why-medical-meetings-will-never-be-the-same/2478276/In the wake of the COVID-19 pandemic, the virtual medical meeting is now the norm. And while it’s admirable that key data are being disseminated (often for free), there is no escaping the fact that it is a fundamentally different and lesser experience, according to commentary